Curaleaf Holdings enters the Australian market with its QMID inhalation device, signaling a broader push into the Oceania medical cannabis sector alongside partner Jupiter Research.
Curaleaf Holdings is expanding its international medical cannabis operations by launching the Que Medical Inhalation Device (QMID) in Australia and New Zealand. This follows the successful registration of the device with Australia's Therapeutic Goods Administration (TGA), marking a significant milestone in the company's strategy to increase its global footprint in the medical cannabis sector.
The Que Medical Inhalation Device is a medical device developed in partnership with Jupiter Research LLC, now available for patients in Australia and New Zealand.
The device was registered by Australia's Therapeutic Goods Administration (TGA).
Curaleaf Holdings has officially launched its Que Medical Inhalation Device (QMID) in Australia following successful registration with the Therapeutic Goods Administration. This strategic expansion, executed in partnership with Jupiter Research LLC, marks a significant milestone in the company's international growth strategy for its medical cannabis portfolio.
The TGA registration allows Curaleaf to legally market and distribute its medical inhalation device within the Australian market, expanding its international footprint.